Style | Citing Format |
---|---|
MLA | Ghafelehbashi SH, et al.. "Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients." Middle East Journal of Cancer, vol. 13, no. 4, 2022, pp. 573-580. |
APA | Ghafelehbashi SH, Sadeghizadeh D, Rohollah F, Pahlavanneshan S, Sadeghizadeh M (2022). Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients. Middle East Journal of Cancer, 13(4), 573-580. |
Chicago | Ghafelehbashi SH, Sadeghizadeh D, Rohollah F, Pahlavanneshan S, Sadeghizadeh M. "Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients." Middle East Journal of Cancer 13, no. 4 (2022): 573-580. |
Harvard | Ghafelehbashi SH et al. (2022) 'Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients', Middle East Journal of Cancer, 13(4), pp. 573-580. |
Vancouver | Ghafelehbashi SH, Sadeghizadeh D, Rohollah F, Pahlavanneshan S, Sadeghizadeh M. Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients. Middle East Journal of Cancer. 2022;13(4):573-580. |
BibTex | @article{ author = {Ghafelehbashi SH and Sadeghizadeh D and Rohollah F and Pahlavanneshan S and Sadeghizadeh M}, title = {Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients}, journal = {Middle East Journal of Cancer}, volume = {13}, number = {4}, pages = {573-580}, year = {2022} } |
RIS | TY - JOUR AU - Ghafelehbashi SH AU - Sadeghizadeh D AU - Rohollah F AU - Pahlavanneshan S AU - Sadeghizadeh M TI - Evaluation of the Expression Levels of Notch Signaling Pathway-Related Genes; Jag1, Cxcr4, and Mib1 in Acute Myeloid Leukemia Patients JO - Middle East Journal of Cancer VL - 13 IS - 4 SP - 573 EP - 580 PY - 2022 ER - |